The US Food and Drug Administration (FDA) today approved tadalafil (Cialis, Eli Lilly), a phosphodiesterase-5 inhibitor, to also treat the signs and symptoms of benign prostatic hyperplasia (BPH) as well as a combination of BPH and erectile dysfunction (ED) when the conditions coincide.
之前大家應該看過一連串的升級歷史了：
加大容量，更加快速度！WD 2.5 吋 blue scorpio 500GB MAC 更換記
是的，現在我們又要進階了：
上1T！！
硬碟資訊你可以參考這邊：http://www.wdc.com/en/products/products.aspx?id=140
國人胰臟癌的診斷方式依行政院衛生署的統計中有細胞學或組織病理學診斷的病例中在民國87年僅為57.62﹪，而在有組織病理診斷的病例中又以腺癌最為常見，佔男性病例的80.56﹪，女性病例的85.64﹪，與國外95﹪以上為腺癌有所差別。
N Engl J Med 2011; 365:1201-1211September 29, 2011
根據發表於美國骨骼與骨質研究協會(ASBMR)2011年會的研究，接受腎臟移植的病患在移植後及早停用以皮質類固醇為基礎的免疫抑制療法(CSBI)可以顯著降低骨折發生率。
根據線上美國腎臟學會期刊的一項世代研究結果，血中的纖維母細胞生長因子-23(FGF-23)數值與慢性腎臟病(CKD)患者的結果不佳有關。
惡性軟組織肉瘤的治療方式
一、簡介
惡性肉瘤是指由中胚層間葉細胞癌化所產生的各種少見、臨床與病理特性互異的惡性腫瘤，他們在分類上相當複雜，但通常可大致分為兩類：一類是由各種軟組織所發生的，包括脂肪、骨骼肌與平滑肌、神經及神經鞘、血管及各種結締組織；另一類則是由骨骼所發生的惡性肉瘤。本文將討論前者，也就是各種軟組織所發生的惡性肉瘤。
臭蟲（bedbugs）不會殺死你，但用來殺死牠們的毒藥可能會殺死你。根據美國疾病管制局最新的發病率和死亡率週報（Morbidity and Mortality Weekly Report）顯示，接觸用來控制臭蟲的殺蟲劑在2003年至2010年間，導致1人死亡，超過100人生病。
根據線上刊載於8月24日美國臨床營養期刊(American Journal of Clinical Nutrition)的前瞻世代研究結果，多攝取omega-3 (n-3)長鏈多元不飽和脂肪酸(LC-PUFA)對婦女的心臟健康有幫助。
On September 26, 2011, FDA informed the public that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills. FDA has completed its review of the two 2011 studies that looked at the risk of blood clots for women who use drospirenone-containing birth control pills, previously mentioned in FDA's Drug Safety Communication issued on May 31, 2011 .1,2 FDA is continuing its review of a separate FDA-funded study that evaluated the risk of blood clots in users of several different hormonal birth control products (contraceptives). Preliminary results of the FDA-funded study suggest an approximately 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills compared to users of other hormonal contraceptives.
The European Medicines Agency (EMA) recommends restricting the use of the antiarrhythmic medication dronedarone (Multaq, Sanofi-Aventis) [1]. The committee states that because of the increased risk of liver, lung, and cardiovascular adverse events, dronedarone "should only be prescribed after alternative treatment options have been considered." Patients currently taking dronedarone should have their treatment reassessed by their physician at their next scheduled visit, the EMA reports.
The US Food and Drug Administration (FDA) today approved eculizumab (Soliris, Alexion Pharmaceuticals) as the first drug to treat atypical hemolytic uremic syndrome (aHUS), a rare and chronic blood disease that disproportionately affects children.
The European Medicines Agency has changed its recommendations for suppositories that contain terpenic derivatives. It now says that they should not be used in children younger than 30 months or in children who have experienced febrile convulsion, epilepsy, or recent anorectal lesions.
Fanelli M; Kupperman E; Lautenbach E; Edelstein PH; Margolis DJ
Department of Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 815 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104. dmargoli@cceb.med.upenn.edu.
Clinical Context
On August 10, the US Food and Drug Administration (FDA) approved Complera, a combination of the nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir and emtricitabine, for treatment of HIV infection. This combination drug results in the same blood levels as each of the 3 drugs individually, according to the findings of a bioequivalence study. Approval of Complera was based on the ECHO and THRIVE phase 3 randomized trials of rilpivirine, without performance of any new trials.
What is the optimal dose of intravenous methylprednisolone for acute asthma exacerbation?
A new generation of genomic technologies permits the increased collection of data on large study populations.1,2 New methods in informatics facilitate the integration of diverse types of information with genomic data in disease research. As a result, researchers are learning more about the genetic bases of disease and response to drugs.3-6 Genetic tests, including many that are offered directly to the consumer, are growing in number and clinical relevance. Genomic knowledge and technologies are also being adopted in areas distant from human health. Here, I describe evolving policies pertinent to genetic and genomic research, the integration of genetics into clinical care, and the broader issues raised by genetic technologies and information.
醫藥類 (14) 電腦知識 (3) 心情點滴 (3) 部落格摘要 (1) 其他知識 (1)
或請google "Mulicia"
